Total RadIoTherapy of Oligometastatic caNcerS

This is a Phase III non-blinded randomized study evaluating patients with oligometastatic cancers (up to 10 metastases). Subjects are randomized 1:1 to stereotactic ablative radiotherapy (SABR) plus standard of care therapies versus standard of care therapies alone. The investigators will measure progression-free survival at 2 years based on the hypothesis that subjects treated with SABR plus standard of care will not experience disease progression for a longer period of time than subjects treated with standard of care alone. The investigators will also measure overall survival and safety of SABR, as well as biomarkers that may help predict, in the future, who will benefit from the SABR treatment.

NCT Number	NCT06587490
Lead Sponsor	University of California, San Diego
Conditions	Oligometastatic Malignant Solid Neoplasm
Enrollment	300 participants
Start Date	2024-11-12
Primary Completion	2033-11 (estimated)
Study Completion	2034-11 (estimated)
Updated on ClinicalTrials.gov	2025-10-14